Clinical trial
Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
NCT00278382 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00278382 |
|---|---|
| Title | Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma |
| Official title | A Phase 2 Study of BAY 43-9006 (IND 69896) in Chemosensitive Relapsed Aggressive Non-Hodgkin's Lymphomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anaplastic Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma |
| Intervention type | Drug, Other |
| Interventions | sorafenib tosylate, laboratory biomarker analysis |
| Enrollment | 33 |
| Start date | Oct 1, 2005 |
| Primary completion | Dec 1, 2007 |
| First posted | Jan 18, 2006 |
| Last update posted | Feb 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: